The Thyroid Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thyroid Cancer. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued products.

GlobalData tracks 168 drugs in development for Thyroid Cancer by 126 companies/universities/institutes. The top development phase for Thyroid Cancer is phase ii with 66 drugs in that stage. The Thyroid Cancer pipeline has 153 drugs in development by companies and 15 by universities/ institutes. Some of the companies in the Thyroid Cancer pipeline products market are: Novartis, F. Hoffmann-La Roche and Bristol-Myers Squibb.

The key targets in the Thyroid Cancer pipeline products market include Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC, Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC, and Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC

The key mechanisms of action in the Thyroid Cancer pipeline product include Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC Inhibitor with 29 drugs in Pre-Registration. The Thyroid Cancer pipeline products include 15 routes of administration with the top ROA being Oral and 17 key molecule types in the Thyroid Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Thyroid Cancer overview

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in neck and throat, and swollen lymph nodes in the neck. Predisposing factors include female sex, high levels of radiation exposure, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

For a complete picture of Thyroid Cancer’s pipeline drug market, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.